Pharmacokinetics of Prophylactic Ampicillin–Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass
Biological and Pharmaceutical Bulletin 38 巻 11 号
1817-1821 頁
2015-11-01 発行
アクセス数 : 682 件
ダウンロード数 : 134 件
今月のアクセス数 : 3 件
今月のダウンロード数 : 4 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00046714
ファイル情報(添付) |
BiolPharmBull_38_1817.pdf
556 KB
種類 :
全文
|
タイトル ( eng ) |
Pharmacokinetics of Prophylactic Ampicillin–Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass
|
作成者 |
Matsumoto Kazuaki
Watanabe Erika
Yamamoto Hiroyuki
Imoto Yutaka
Takeda Yasuo
|
収録物名 |
Biological and Pharmaceutical Bulletin
|
巻 | 38 |
号 | 11 |
開始ページ | 1817 |
終了ページ | 1821 |
抄録 |
Antibiotic concentrations must be maintained at an adequate level throughout cardiovascular surgery to prevent surgical site infection. This study aimed to determine the most appropriate timing for intraoperative repeated dosing of ampicillin–sulbactam, a commonly used antibiotic prophylaxis regimen, to maintain adequate concentrations throughout the course of cardiovascular surgery with cardiopulmonary bypass (CPB). The total plasma concentrations of ampicillin were monitored in 8 patients after ampicillin (1 g)–sulbactam (0.5 g) administration via initial intravenous infusion and subsequent CPB priming. Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin. The mean values for the volume of distribution, elimination rate constant, elimination half-life, and total clearance of ampicillin were 15.8±4.1 L, 0.505±0.186 h-1, 1.52±0.47 h, and 7.72±2.72 L/h, respectively. When ampicillin (1 g)–sulbactam (0.5 g) was intravenously administered every 3, 4, 6, and 12 h after the start of CPB, the predicted free trough plasma concentrations of ampicillin were 15.20, 8.25, 2.74, and 0.13 μg/mL, respectively. Therefore, an every-6-h regimen was needed to maintain the free ampicillin concentration at more than 2 μg/mL during cardiovascular surgery with CPB. We suggest that the dose and dosing interval for ampicillin–sulbactam should be adjusted to optimize the efficacy and safety of treatment, according to the minimum inhibitory concentrations for methicillin-sensitive Staphylococcus aureus isolates at each institution. Registration number: UMIN000007356.
|
著者キーワード |
ampicillin
sulbactam
cardiovascular surgery
prophylaxis
cardiopulmonary bypass
|
NDC分類 |
医学 [ 490 ]
|
言語 |
英語
|
資源タイプ | 学術雑誌論文 |
出版者 |
The Pharmaceutical Society of Japan
|
発行日 | 2015-11-01 |
権利情報 |
Copyright (c) 2015 The Pharmaceutical Society of Japan
|
出版タイプ | Version of Record(出版社版。早期公開を含む) |
アクセス権 | オープンアクセス |
収録物識別子 |
[ISSN] 0918-6158
[ISSN] 1347-5215
[NCID] AA10885497
[DOI] 10.1248/bpb.b15-00334
[DOI] https://doi.org/10.1248/bpb.b15-00334
[NAID] 130005106382
|